1. GB590 Corporate Social Responsibility Prof. Ray Kalinski By Willette Marchany Rivera December 13, 2010

2.  Introduction: Industry Overview  Objectives  Industry Audit ◦ Social ◦ Environmental ◦ Economic  Industry Stakeholders Analysis ◦ Stockholders ◦ Consumers ◦ Employees  Conclusion  References

3.  Ethical drugs for human consumption at ex-factory prices: ◦ Research ◦ Development ◦ Manufacture ◦ Marketing  5.3% industry market value growth in 2009 translates to $1,071.7 billion  Expected market value increase of 30.9% from 2009 to 2014  Pharmaceuticals is the largest segment: 75.7% of the industry's total value.  Americas accounts for 50.5% of the industry value

4.  Track important development of social, environmental, and economic issues affecting the pharmaceutical industry  Explore the positions and perspectives of the various stakeholders with regards to the social, environmental, and economic matters affecting the industry

5.  Use of natural/alternative medicine and “green” trends  Safety concerns about drugs and their secondary effects  Poor countries where the indigent can’t pay to acquire medicines  Treating symptoms instead of finding a cure for the disease or condition  Marketing methods and direct to consumer advertising. Industry Audit

6.  Strict environmental laws in United States and Europe  Fuel consumption and air pollution  Climate change ◦ Volatile Organic Compounds (VOC) ◦ Ozone Depleting Compounds (ODC)  Water usage, consumption and treatment  Energy efficiency  Waste and efficient packaging Industry Audit

7.  Research & development costs  High price of pharmaceutical drugs  International trade: Safety regulations vary between countries pose barriers to entry  Tax increases and changes in fiscal exemptions  Freight costs: Fuel prices and Transportation Security Agency regulations Industry Audit

8.  Profits  Drug patents  Ethical behavior SuppliersSocietyEnvironment Employees Medical Professionals Patients Stockholders &. Investors Industry Stakeholders

9.  Consumer’s rights ◦ Receive accurate information  Human rights ◦ The right to health SuppliersSocietyEnvironment Employees Medical Professionals Patients Stockholders &. Investors Industry Stakeholders

10.  Physicians & Pharmaceutical Medicine  Rewarding ethical behavior  Best companies to work for SuppliersSocietyEnvironment Employees Medical Professionals Patients Stockholders &. Investors Industry Stakeholders

11.  Pharmaceutical industry is strong and profitable  Several ethical concerns regarding drug safety, efficiency and sustainability

12. Alternative Medicine Industry Overview. (2009, April 27). Themedica: Global Health Marketplace. Retrieved December 13, 2010 from http://www.themedica.com/articles/2009/04/alternative-medicines-industry.html Kitsis, E. A. (2009). Rx for the Pharmaceutical Industry: Call Your Doctors. Hastings Center Report, 39(4), 18-21. Retrieved from EBSCOhost. Lawrence, A. T. (2011). Merck, the FDA, and the Vioxx recall. In Lawrence, A. T. Weber, J., Business and Society: Stakeholders, Ethics, Public Policy (pp.480- 489). New York: McGraw-Hill. Luthra, R. (2006, November). Health-care patents and interests of patients. Bulletin of the World Health Organization, 84 (11). (pp.919) Springfield, MA: Woman’s Health Education Center Melia, M. (2007, November 26). Plantas farmacéuticas abandonan Puerto Rico. La Voz. Retrieved December 13, 2010 from http://www.azcentral.com/lavoz/spanish/us/articles/us_130354.html Muhairwe, A. (2008). Harmonization of drug regulation in East Africa: the way forward. Presentations from 13th International Conference of Drug Regulatory Authorities (ICDRA). World Health Organization. Retrieved December 13,2010 from http://www.who.int/medicines/areas/quality_safety/regulation _legislation/icdra/2_Uganda_HarmonisationDrugRegulation-EastAfrica.pdf Pharmaceuticals, Biotechnology & Life Sciences Industry Profile: Global. (2010). Pharmaceuticals, Biotechnology & Life Sciences Industry Profile: Global, 1. Retrieved from EBSCOhost. Slowik, E. (2010). Newton: Big pharma seeks partners, not purchases. Grand Rapids Business Journal, 28(41), 3. Retrieved from EBSCOhost. The right to the highest attainable standard of health: General Comment No. 14. (2000). United Nations Economic and Social Council. Retrieved December 12, 2010 from http://www.unhchr.ch/tbs/doc.nsf/%28symbol%29/E.C.12.2000.4.En